The first studies comparing HER2-low status showed discordance of HER2 expression (HER2-low versus HER2-zero) in up to 32% of cases, with a tendency for HER2-low expression to increase in advanced breast cancer [13, 28]. This evidence concerns the gene ERBB2 and breast cancer.